MMP7 Antikörper (AA 151-250)
-
- Target Alle MMP7 Antikörper anzeigen
- MMP7 (Matrix Metallopeptidase 7 (Matrilysin, Uterine) (MMP7))
-
Bindungsspezifität
- AA 151-250
-
Reaktivität
- Human, Maus
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser MMP7 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))
- Kreuzreaktivität
- Human, Maus
- Homologie
- Rat
- Aufreinigung
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from mouse MMP7
- Isotyp
- IgG
- Top Product
- Discover our top product MMP7 Primärantikörper
-
-
- Applikationshinweise
-
WB 1:300-5000
ELISA 1:500-1000
FCM 1:20-100
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 μg/μL
- Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- Haltbarkeit
- 12 months
-
-
Biocompatibility of Intensified Decellularized Equine Carotid Arteries in a Rat Subcutaneous Implantation Model and in a Human In Vitro Model." in: Tissue engineering. Part A, (2017) (PubMed).
: "TP53 modulating agent, CP-31398 enhances antitumor effects of ODC inhibitor in mouse model of urinary bladder transitional cell carcinoma." in: American journal of cancer research, Vol. 5, Issue 10, pp. 3030-41, (2015) (PubMed).
: "Activating transcription factor 4 promotes esophageal squamous cell carcinoma invasion and metastasis in mice and is associated with poor prognosis in human patients." in: PLoS ONE, Vol. 9, Issue 7, pp. e103882, (2014) (PubMed).
: "
-
Biocompatibility of Intensified Decellularized Equine Carotid Arteries in a Rat Subcutaneous Implantation Model and in a Human In Vitro Model." in: Tissue engineering. Part A, (2017) (PubMed).
-
- Target
- MMP7 (Matrix Metallopeptidase 7 (Matrilysin, Uterine) (MMP7))
- Andere Bezeichnung
- MMP-7 (MMP7 Produkte)
- Synonyme
- MAT antikoerper, MPMM antikoerper, MMP-7 antikoerper, MPSL1 antikoerper, PUMP-1 antikoerper, matrilysin antikoerper, LOC727698 antikoerper, MMP7 antikoerper, Matrilysin antikoerper, matrix metallopeptidase 7 antikoerper, MMP7 antikoerper, Mmp7 antikoerper
- Hintergrund
-
Synonyms: Matrilysin, Matrilysin uterine, Matrin, Matrix Metalloproteinase 7, MMP 7, MMP7, MPSL1, PUMP 1, Pump 1 protease, PUMP1, Uterine Matrilysin, Uterine metalloproteinase.
Background: Matrix metalloproteinase-7 (MMP-7) also known as matrilysin and PUMP (EC 3.4.24.23) cleaves a number of substrates including collagen types IV and X, elastin, fibronectin, gelatin, laminin and proteoglycans. MMP-7 is closely related to the stromelysin family members but is encoded by a different gene. MMP-7 is the smallest of all the MMPs consisting of a pro-peptide domain and a catalytic domain. It lacks the hemopexin-like domain common to other members of the MMPs. MMP-7 is secreted as a 28kD proenzyme and can be activated in vitro by organomercurials and trypsin and in vivo by MMP-3 to a 18kD active MMP-7 enzyme. Once activated, MMP-7 can activate pro-MMP-1 and pro-MMP-9 but not pro-MMP-2. MMP-7 is widely expressed having been reported in elevated levels in cycling endometrium as well as in colorectal cancers and adenomas, hepatocellular carcinomas, rectal carcinomas, and approximately 50 % of gliomas.
- Pathways
- Production of Molecular Mediator of Immune Response
-